Guerbet Vendor's profile
Guerbet to double its turnover with the acquisition of Mallinckrodt’s contrast media and delivery systems business Guerbet (FR0000032526 GBT) announced today that it has entered into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems busines...
Frost & Sullivan Applauds Guerbet’s Novel, Syringe-free CT Contrast Injector, FlowSens®FlowSens® is more affordable, innovative and offers faster turnaround times than its competing solutionsMOUNTAIN VIEW, Calif. Based on its recent analysis of the market for contrast auto-injector compu...
Revenue at 30 September 2015
星期二, 2015年 九月 29日
Revenue at 30 September 2015€343.6 million; +10.2% at constant exchange rates Villepinte, 22 October 2015 – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting third-quarter revenue up by 14.6% at constant exchange rates. Cumulat...
Guerbet signs agreement with Kyuan for promotion & distribution of Lipiodol® Ultra-Fluid in ChinaGuerbet (GBT) announced today the signing of an agreement with Beijing Kyuan Pharmaceutical Co., Ltd., one of the major pharmaceutical drugs distributors & importers in the Chinese market...
Guerbet signs an agreement with Fuji Pharma to market its range of contrast media in Japan Guerbet (GBT) announces an agreement with Fuji Pharma Co., Ltd, a leading provider of contrast media to distribute and promote its range of contrast media for MRI, X-Ray imaging and interventional radi...
To feature here : Get in touch
Olea Medical® case report on early & late MR diffusion follow-up of a stroke using CT perfusion.
Olea Medical® literature meta-analysis on CTP thresholds in acute stroke
Increasing surgical confidence with intraoperative 3D information in a pelvic fracture
Ziehm Vision RFD Hybrid Edition: Mobility and flexibility – the difference in an emergency